Enliven Therapeutics (NASDAQ:ELVN) Given New $48.00 Price Target at HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN) had its price target increased by HC Wainwright from $40.00 to $48.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on ELVN. Robert W. Baird upped their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, June 16th. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, Jones Trading decreased their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $41.20.

Enliven Therapeutics Stock Up 5.0%

Shares of ELVN opened at $20.64 on Wednesday. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03. The firm’s fifty day moving average is $19.49 and its two-hundred day moving average is $20.40. The stock has a market cap of $1.01 billion, a PE ratio of -10.75 and a beta of 0.83.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $18.04, for a total transaction of $120,272.68. Following the sale, the chief operating officer directly owned 316,643 shares in the company, valued at $5,712,239.72. This represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total transaction of $277,250.00. Following the sale, the chief executive officer owned 952,892 shares in the company, valued at $21,135,144.56. This trade represents a 1.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 100,111 shares of company stock valued at $1,939,549 over the last 90 days. 25.90% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ELVN. Polar Capital Holdings Plc increased its stake in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the period. Boxer Capital Management LLC purchased a new stake in Enliven Therapeutics during the fourth quarter worth about $15,106,000. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock worth $30,001,000 after purchasing an additional 290,153 shares during the period. FMR LLC increased its stake in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock worth $146,157,000 after purchasing an additional 199,692 shares during the period. Finally, Pictet Asset Management Holding SA increased its stake in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.